A retrospective, multicenter study of efficacy of atezolizumab-bevacizumab therapy in hepatocellular carcinoma patients treated with TKIs
Latest Information Update: 14 Nov 2022
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 01 Nov 2022 Results assessing real-world feasibility of atezolizumab-bevacizumab in patients treated with tyrosine-kinase inhibitors, published in the Digestive and Liver Disease
- 22 Aug 2022 New trial record
- 26 Jun 2022 Results (n=423) presented at The International Liver Congress 2022.